The short version of lyophilized powder fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-09-19. Anything still debated is marked as such rather than presented as settled.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C152H252N44O42 | Cited for the form without the drug affinity complex |
| Molecular weight | About 3368 Da | Reported value for modified GRF(1-29) |
| Appearance | White to off-white powder | Lyophilised solid as usually supplied |
| Solubility | Soluble in water and polar solvents | Clarity depends on purity and salt content |
| Typical storage | -20 C or below, dry | Protect from light and repeated warming cycles |
Lyophilized material is typically stored at minus twenty degrees Celsius or lower. Keeping the vial dry and protected from light preserves peptide integrity. Repeated freeze-thaw cycles can cause aggregation or loss of activity. Once dissolved, solutions are generally kept at two to eight degrees Celsius. Stability data for reconstituted solutions vary, and long-term behavior is not fully established. Working aliquots reduce the number of times a stock container is opened.
Reverse-phase high-performance liquid chromatography is the standard tool for purity assessment. The technique separates the target peptide from truncated or modified byproducts. Mass spectrometry confirms molecular weight and supports sequence verification. Electrospray ionization and matrix-assisted laser desorption are both used. Amino acid analysis provides an independent check on composition. Purity values are commonly reported as area percentage from the chromatogram. Residual trifluoroacetate and water content are also measured in many quality programs.
Batch-to-batch consistency depends on solid-phase peptide synthesis and subsequent purification. Coupling efficiency, resin choice, and cleavage conditions all affect the final profile. Counter-ion content and moisture can shift the apparent mass of a batch. Documentation typically includes a certificate of analysis with chromatograms and spectra. Independent verification by a second laboratory is sometimes requested. Whether a given certificate reflects the actual vial contents depends on chain of custody. Analytical methods themselves carry uncertainty that should be stated alongside results.
Lyophilized material is generally stable for extended periods when held at minus twenty degrees Celsius or below and protected from moisture and light. In solution the peptide is more labile; bond hydrolysis, aggregation and oxidation of susceptible residues all proceed faster at ambient temperature. Repeated freeze and thaw cycles should be avoided because they promote clumping and loss of soluble material. The conjugated variant adds a further consideration, since the maleimide group can hydrolyze in aqueous buffer and lose its ability to react with albumin.
Laboratory handling centers on minimizing exposure to water, heat and oxygen before use. Working solutions are typically prepared in sterile water or a mild buffer, and any residual particulate matter is removed by filtration. When the powder dissolves slowly, a small proportion of acetonitrile or dilute acetic acid is sometimes added as a co-solvent. Containers are kept sealed and desiccated between uses. Records of lot number, reconstitution date and storage conditions support later comparison of results across experiments.
Identity and purity are established with reversed phase high performance liquid chromatography coupled to mass spectrometry. The chromatographic step separates the target peptide from truncated sequences and deletion products, while the mass measurement confirms the expected molecular weight to within a fraction of a dalton. Because the two common variants differ by the presence of the linker, mass alone can distinguish them in the unconjugated state. Amino acid analysis and peptide mapping are used when sequence level confirmation is required.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
. At the moment a particle leaves the control volume, its age is the total time that the particle has spent inside the control volume, which is known as its residence time. The frequency of occurrence of the age
Maisie Mosco (7 December 1924 – 31 October 2011) wrote 16 novels between 1979 and 1998. These include the 'Almonds and Raisins' series (Almonds & Raisins, Scattered Seed, Children's Children, Out of the Ashes, and New Beginnings), about a Jewish family who around 1900 fled anti-Jewish pogroms in the Russian Empire and emigrated to north Manchester in England. These books contained elements of her own family history and were dramatized for BBC Radio 4. Michael Moritz (b. 1954) billionaire venture capitalist, philanthropist, author, journalist; works for Sequoia Capital, wrote history of Apple Inc., The Little Kingdom, and Going for Broke: Lee Iacocca's Battle to Save Chrysler; was writer at Time magazine and member of board of directors of Google; founded Technologic Partners; named as the No. 1 venture capitalist on the Forbes Midas List; appointed Knight Commander of the Order of the British Empire (KBE). Claus Moser, Baron Moser, (24 November 1922 – 4 September 2015) was a British statistician, scholar and author who made major contributions in both academia and the Civil Service.
A 2018 literature review of 740 records of surgeries that included recurrence rates found that primary midline closure surgeries resulted in a 67.9% recurrence rate within 20 years, and recommended that they should be discontinued due to the high recurrence rate. Incision and drainage had a recurrence rate of 25.9% within 2 years, up to 40.2% in 5 years. Phenol treatment has a recurrence rate of 14.1% at 2 years and 40.4% at 5 years. A 2024 study involving 667 people found that, compared with tissue-removing surgery, minor procedures (such as draining and pit-picking) were associated with less pain, fewer complications and a faster recovery. However, minor surgeries were less likely to resolve the condition. Surgeons can also excise the sinus and repair it with a reconstructive flap technique, such as a "cleft lift" procedure or Z-plasty, usually done under general anesthetic. This approach is especially useful for complicated or recurring pilonidal disease, leaves little scar tissue, and flattens the region between the buttocks, reducing the risk of recurrence. This approach typically results in a more rapid recovery than traditional surgery; however, there are fewer surgeons trained in the cleft lift procedure, and it consequently may not be as accessible to patients, depending on their location. Meta-analysis shows recurrence rates were lower in open healing than with primary closure (RR 0.60, 95% CI 0.42 to 0.87), at the expense of healing time.
== Biomarkers of disease == It is important to acknowledge the biomarkers of third-hand smoke because they theoretically indicate the severity and presence of disease. In a recent study involving mice, THS biomarkers were discovered after four weeks of initial exposure at equivalent levels to those found in the homes of people who smoke. Researchers used a system that mimicked exposure to humans and sought out biomarkers found in serum, liver, and brain tissues in the mice. The mice were then exposed to THS at varying months and as early as one month, they began to show signs of increased circulating inflammatory cytokines, tumor necrosis factor, granulocyte macrophage colony stimulating factor, and an increase in the stress hormone epinephrine. Damage from THS exposure continued after two, four, and six months. Such damages included oxidative stress and molecular damage. In a small controlled study of healthy nonsmoking adults, acute dermal exposure to third-hand smoke increased urinary biomarkers of oxidative damage to DNA, lipids and proteins and altered the plasma proteome in a pattern similar to that observed in cigarette smokers, including activation of pathways associated with inflammatory skin disease. Some of the mice also became hyperglycemic and hyperinsulinimic, which could mean that insulin resistance could be a consequence of long-term exposure. This study implies that increased exposure time to THS can have dramatic effects.
Sources: en.wikipedia.org
== Council for Scientific and Industrial Research (CSIR) == Immediately following Prime Minister Billy Hughes' 22 December 1915 "National Laboratory Conference" announcement at a Melbourne University luncheon, the British Science Guild sent the Prime Minister a copy of its (hitherto ignored) 1914 Report, with Robertson's (1913) Report on the Scope and Administration of an Institute for Scientific Research in Australia (BR.13) appended to it. The formal gathering was convened in Melbourne on 5 January 1916; and a Commonwealth Advisory Council of Science and Industry was established, "with over twenty members representing a cross-section of scientific, state, and business interests". On 12 December 1916, the Council's Acting Secretary, Gerald Lightfoot, submitted his Memorandum on the Organization of Scientific Research Institutions in the United States of America (GL.1), to the Council to send on to the Prime Minister. On 14 September 1920, an Institute of Science and Industry, with Sir George Knibbs as its Director, was established by the Institute of Science and Industry Act 1920 (CA.1). On 21 June 1926, the Council for Scientific and Industrial Research (CSIR) was created by the Science and Industry Research Act 1926 (CA.2). The Council consisted of eleven members: three Commonwealth nominees, who formed the Executive Committee (and one of whom would be appointed chairman), and, in addition to the six State chairmen, another two co-opted members.
== Prognosis == Stroke and other cardiovascular diseases are related to OSA, and those under the age of 70 have an increased risk of early death. Persons with sleep apnea have a 30% higher risk of heart attack or death than those unaffected. In severe and prolonged cases, increased in pulmonary pressures are transmitted to the right side of the heart. This can result in a severe form of congestive heart failure known as cor pulmonale. Diastolic function of the heart also becomes affected. Elevated arterial pressure (i.e., hypertension) can be a consequence of OSA syndrome. When OSA causes hypertension, it is distinctive in that, unlike most cases (so-called essential hypertension), the readings do not drop significantly when the individual is sleeping (non-dipper) or even increase (inverted dipper). Without treatment, the sleep deprivation and lack of oxygen caused by sleep apnea increases health risks such as cardiovascular disease, aortic disease (e.g., aortic aneurysm), high blood pressure, stroke, diabetes, clinical depression, weight gain, obesity, and even death. OSA is associated with cognitive impairment, including deficits in inductive and deductive reasoning, attention, vigilance, learning, executive functions, and episodic and working memory. OSA is associated with increased risk for developing mild cognitive impairment and dementia, and has been associated with neuroanatomical changes (reductions in volumes of the hippocampus, and gray matter volume of the frontal and parietal lobes) which can however be at least in part reversed with CPAP treatment.
An overlap syndrome is a medical condition which shares features of at least two more widely recognised disorders. Examples of overlap syndromes can be found in many medical specialties such as overlapping connective tissue disorders in rheumatology, and overlapping genetic disorders in cardiology.
Sources: en.wikipedia.org
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.
No regulatory agency has approved CJC-1295 for clinical use. Human trials were conducted in the 2000s, but the development programme was discontinued before any marketing application succeeded. Material sold today is offered as a research chemical, and its purity depends on the supplier.
Sermorelin is an unmodified fragment of growth hormone-releasing hormone and is cleared quickly. CJC-1295 contains substitutions that resist breakdown, and the form with a drug affinity complex persists much longer. Both act at the same receptor but differ substantially in duration of action.
No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.